Wednesday, June 20, 2007

Dr. John LaMattina's view of PFE stock

From the Associated Press yesterday:
Pfizer Senior Vice President John L. Lamattina Sells 36,066 Shares NEW YORK (AP) -- A senior vice president of drug maker Pfizer Inc. sold 36,066 shares of common stock, according to a Securities and Exchange Commission filing Monday.

In a Form 4 filed with the SEC, John L. Lamattina reported he sold the shares Friday for $26.48 apiece.

Today we hear that:

1. Pfizer Stops Developing Coley Cancer Drug

2. FDA Delays Ruling on Pfizer AIDS Drug

Pharmalyst is sure that the timing is purely coincidental (but is interesting nevertheless). These sort of setbacks coupled with other failures such as Exubera and torcetrapib are probably the reasons that Dr LaMattina is being eased out of his current position as the head of R&D at Pfizer.


Anonymous said...

Martha Stewart went to jail for something similar!

Anonymous said...

Lamattina had previously announced his retirement (not by choice). It is unsurprising that he'd sell parts of holding. I doubt if it has anything to do with the news out of the company. Given his current position, stock sales are tightly regulated and it is likely that this was planned prior to last week.

PFE stock price Today said...

I am looking forward to checking out more posts!